PDS Biotechnology (NASDAQ:PDSB) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS

PDS Biotechnology (NASDAQ:PDSB) issued its quarterly earnings results on Monday. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.06, FiscalAI reports.

PDS Biotechnology Stock Performance

NASDAQ:PDSB opened at $0.54 on Monday. PDS Biotechnology has a 12 month low of $0.52 and a 12 month high of $1.92. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $28.36 million, a price-to-earnings ratio of -0.66 and a beta of 1.20. The firm has a fifty day simple moving average of $0.72 and a two-hundred day simple moving average of $0.86.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $9.00.

Institutional Trading of PDS Biotechnology

Large investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new position in PDS Biotechnology during the 4th quarter worth approximately $25,000. Marshall Wace LLP acquired a new stake in PDS Biotechnology in the second quarter valued at approximately $91,000. Jane Street Group LLC bought a new stake in shares of PDS Biotechnology during the second quarter valued at approximately $92,000. Susquehanna International Group LLP increased its holdings in shares of PDS Biotechnology by 603.7% during the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after acquiring an additional 80,937 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its position in shares of PDS Biotechnology by 117.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock worth $151,000 after purchasing an additional 106,300 shares during the period. 26.84% of the stock is currently owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.